BioPharm International - October 2020

BioPharm- October - Regulatory Sourcebook

Issue link: https://www.e-digitaleditions.com/i/1300450

Contents of this Issue

Navigation

Page 44 of 59

www.biopharminternational.com October 2020 BioPharm International eBook 45 Viewpoint: Precompetitive Collaboration Drives Pharma Industry Innovation The IQ Consortium marks a decade of impactful innovation of collaboration through a network of pharmaceutical companies driving change for the bio/pharmaceutical industry. P harmaceutical development is a long, risky, and expensive process. In this highly com- petitive market, pharmaceutical compa- nies are under constant pressure to deliver innovation via new therapeutics, new tech- nology, and improved efficiency and effectiveness (1). Precompetitive collaboration is recognized as a mechanism to enhance efficiency, mitigate risks, and share costs that can benefit industry, academia, and government agencies. For the purposes of this view- point, "precompetitive collaboration" may be defined as collaborations between pharmaceutical companies and third parties to produce an efficiency-enhancing advancement or refinement that will be made broadly available to the public (i.e., publication, commercial- ization of a new product). Over the past decade, pharmaceutical consortia have emerged as collaborative forums where indus- Tex vector - Stock.adobe.com MARGARET M. FAUL, CARL L. MCMILLIAN, PIERRE BOULAS, REGINALDO A. SARACENO, MARY DEVLIN CAPIZZI, AND MAUREEN T. CRUZ Regulatory Sourcebook Quality MARGARET M. FAUL* is vice-president, Drug Product Technologies, Process Development, Amgen. CARL L. MCMILLIAN is vice-president, Toxicology, Drug Disposition, PK/PD, Eli Lilly and Company. PIERRE BOULAS is executive director, Product and Technology Development, Biogen. REGINALDO A. SARACENO is director, Material and Analytical Sciences, Boehringer Ingelheim Pharmaceuticals. MARY DEVLIN CAPIZZI is partner, Faegre Drinker Biddle & Reath LLP. MAUREEN T. CRUZ is senior manager, Science, Regulation and Policy, Faegre Drinker Biddle & Reath LLP. All authors are members of the IQ Consortium. *To whom all correspondence should be addressed

Articles in this issue

Links on this page

Archives of this issue

view archives of BioPharm International - October 2020 - BioPharm- October - Regulatory Sourcebook